Ryan Kennedy, MD
Endocrinology, Diabetes & Metabolism · Bristol, TNNPI 1295053759
Payments from drug & device makers
Across 797 payments — averaging $138.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$77K
- Boehringer Ingelheim$11K
- Medtronic$8K
- Lilly USA, LLC$7K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$622
- plus $5K from 33 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 34 | $77,232 |
| Boehringer Ingelheim | 72 | $10,511 |
| Medtronic(2 entities) | 149 | $8,251 |
| Lilly USA, LLC | 97 | $6,921 |
| Novo Nordisk | 100 | $1,315 |
| Sanofi-aventis U.S. LLC | 38 | $622 |
| Dexcom, Inc. | 30 | $613 |
| Amgen(2 entities) | 33 | $573 |
| Bayer | 42 | $567 |
| AstraZeneca(2 entities) | 23 | $534 |
| Corcept Therapeutics | 21 | $387 |
| Abbott | 21 | $355 |
| Radius Health, Inc. | 12 | $285 |
| Insulet Corporation | 13 | $237 |
| Xeris Pharmaceuticals, Inc. | 10 | $209 |
| Novartis | 14 | $205 |
| Esperion Therapeutics, Inc. | 9 | $162 |
| Tandem Diabetes Care, Inc. | 6 | $152 |
| Merck | 10 | $134 |
| AbbVie | 8 | $121 |
| Pfizer | 5 | $115 |
| Clarus Therapeutics Inc. | 14 | $111 |
| BETA Bionics, Inc. | 4 | $95 |
| Ascendis Pharma Endocrinology Inc | 4 | $80 |
| Sequel Med Tech, LLC | 2 | $69 |
| Kyowa Kirin, Inc. | 4 | $61 |
| Averitas Pharma Inc. | 2 | $50 |
| Shire North American Group Inc | 3 | $44 |
| IBSA Pharma Inc. | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Johnson & Johnson | 3 | $41 |
| Cequr Corporation | 1 | $30 |
| Lifescan, Inc. | 2 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $26 |
| Zealand Pharma US, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $14 |
| Recordati_rare_diseases_inc. | 1 | $14 |
How this compares
$110,320 in reported general payments places this provider in the 80th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Bristol
- Stephen SharpNashville$25.9M
- Lisa UsdanMemphis$14.3M
- Kathryn DahirNashville$11M
- David HuffmanChattanooga$2.4M
- Pedro VelasquezMemphis$2.4M
- Craig WierumNashville$1.7M
- Alan CohenMemphis$1.5M
- Terri JerkinsNashville$1.2M
- Pascal DauphinHendersonville$925K
- Aidar GosmanovMemphis$833K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.